| Original language | English (US) |
|---|---|
| Pages (from-to) | 1837-1839 |
| Number of pages | 3 |
| Journal | Cell |
| Volume | 185 |
| Issue number | 11 |
| DOIs | |
| State | Published - May 26 2022 |
Funding
D.B. was supported by a gift from the Joseph and Bessie Feinberg Foundation and grant 1R21 AI166940-01. R.E.S. was supported by NCI R01CA234614, NIAID 2R01AI107301, and NIDDK R01DK121072, Department of Medicine, Weill Cornell Medicine and is an Irma Hirschl Trust Research Award Scholar. N.M. has been supported by the project COV20/00278 from Instituto de Salud Carlos III and from the Ayudas Fundaci\u00F3n BBVA a Equipos de Investigaci\u00F3n Cient\u00EDfica SARS-CoV-2 years COVID-19. A.M. N.M. and J.M.P. received funding from the Innovative Medicines Initiative two Joint Undertaking (JU) under grant agreement no. 101005026, J.M.P. received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences and the Canada 150 Research Chairs Program F18-01336 as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015. L.H. has received a stipend from the biomedical education program (BMEP) in support of her research scholarship at Northwestern in Chicago, USA. D.B. and J.W. are coinventors of patents entitled \u201CActive Low Molecular Weight Variants of Angiotensin Converting Enzyme 2,\u201D \u201CActive low molecular weight variants of Angiotensin Converting Enzyme 2 (ACE2) for the treatment of diseases and conditions of the eye,\u201D and \u201CSoluble ACE2 Variants and Uses Therefor,\u201D which includes the use of prevention and treatment of COVID-19. D.B. is founder of Angiotensin Therapeutics Inc. D.B. has received consulting fees from AstraZeneca, Relypsa, and Tricida, all unrelated to this work. J.W. reports scientific advisor capacity for Angiotensin Therapeutics Inc. R.E.S. is on the scientific advisory board of Miromatrix Inc and is a consultant and speaker for Alnylam Inc. J.M.P. is shareholder of Apeiron Biologics that is developing soluble ACE2 for COVID-19 therapy. D.B. was supported by a gift from the Joseph and Bessie Feinberg Foundation and grant 1R21 AI166940-01. R.E.S. was supported by NCI R01CA234614, NIAID 2R01AI107301, and NIDDK R01DK121072, Department of Medicine, Weill Cornell Medicine and is an Irma Hirschl Trust Research Award Scholar. N.M. has been supported by the project COV20/00278 from Instituto de Salud Carlos III and from the Ayudas Fundaci\u00F3n BBVA a Equipos de Investigaci\u00F3n Cient\u00EDfica SARS-CoV-2 years COVID-19. A.M., N.M., and J.M.P. received funding from the Innovative Medicines Initiative two Joint Undertaking (JU) under grant agreement no. 101005026, J.M.P. received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences and the Canada 150 Research Chairs Program F18-01336 as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015. L.H. has received a stipend from the biomedical education program (BMEP) in support of her research scholarship at Northwestern in Chicago, USA.
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology